| 3.18 0.35 (12.37%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.87 | 1-year : | 5.89 |
| Resists | First : | 4.17 | Second : | 5.05 |
| Pivot price | 4.41  |
|||
| Supports | First : | 2.75 | Second : | 2.28 |
| MAs | MA(5) : | 3.32 |
MA(20) : | 4.56 |
| MA(100) : | 3.63 |
MA(250) : | 2.93 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8.8 |
D(3) : | 7.9 |
| RSI | RSI(14): 22.3 |
|||
| 52-week | High : | 5.07 | Low : | 1.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LSTA ] has closed above bottom band by 11.9%. Bollinger Bands are 229.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.47 - 3.49 | 3.49 - 3.51 |
| Low: | 2.79 - 2.82 | 2.82 - 2.84 |
| Close: | 3.14 - 3.18 | 3.18 - 3.22 |
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Mon, 20 Apr 2026
Lisata Therapeutics Inc (LSTA) - Valuation Measures & Financial Statistics - GuruFocus
Wed, 15 Apr 2026
Lisata Therapeutics says Kuva Labs seeking new financing, tender offer not yet commenced - TradingView
Wed, 15 Apr 2026
Financing delays put Lisata Therapeutics (LSTA) tender offer by Kuva Labs in doubt - Stock Titan
Sat, 04 Apr 2026
Lisata Therapeutics Delays Tender Offer Launch in Merger - The Globe and Mail
Mon, 09 Mar 2026
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances - Proactive financial news
Fri, 06 Mar 2026
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 7.28e+006 (%) |
| Held by Institutions | 19.2 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.806e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 79 % |
| Return on Equity (ttm) | -43.2 % |
| Qtrly Rev. Growth | 170000 % |
| Gross Profit (p.s.) | -81.09 |
| Sales Per Share | -68.05 |
| EBITDA (p.s.) | 153153 |
| Qtrly Earnings Growth | -2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 118.4 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 2.1 |
| Dividend | 0 |
| Forward Dividend | 16930 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|